SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months

Benzinga · Sep 10 22:18

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months

BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS powered with SOPHiA DDM, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (NASDAQ:AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS powered with SOPHiA DDM to 20 locations worldwide over the next 12 months.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months

Risk Disclaimer